Gilead Close to $2 Billion Acquisition of Ouro Medicines, Says FT

• The deal is valued at up to $2 billion, representing a significant investment by Gilead in expanding its pharmaceutical capabilities
• Ouro Medicines is a biotech firm, though the article does not specify its therapeutic areas or pipeline assets
• The acquisition is reportedly nearing completion but has not been officially confirmed by either company

Summary: Gilead Sciences Near $2 Billion Acquisition of Ouro Medicines

Key Transaction Details:

Gilead Sciences is approaching a deal to acquire biotech company Ouro Medicines for up to $2 billion, according to Financial Times sources familiar with the matter. The report was published March 23, 2026.

Companies Involved:

• Gilead Sciences: Major biopharmaceutical company known for its infectious disease and oncology portfolios
• Ouro Medicines: Biotech firm serving as the acquisition target

Market Implications:

This potential acquisition represents a significant strategic move for Gilead as it continues to expand its biotechnology portfolio through M&A activity. At $2 billion, this would be a substantial investment, suggesting Ouro Medicines possesses valuable pipeline assets or technology platforms that align with Gilead's therapeutic focus areas.

The deal underscores ongoing consolidation trends in the biotech sector, where larger pharmaceutical companies are actively seeking to acquire promising smaller firms to bolster their drug development pipelines and maintain competitive positioning.

Notable Context:

While specific details about Ouro Medicines' therapeutic focus or lead programs were not disclosed in the article, the substantial valuation indicates the target company likely has compelling clinical-stage assets or innovative technology of strategic importance to Gilead's long-term growth objectives.

The transaction remains subject to finalization, with no official confirmation from either company at this stage. The timing and final terms have not been publicly disclosed.

Sector: Biopharmaceuticals/Biotechnology

This acquisition would represent another example of large-cap pharmaceutical companies deploying capital to acquire innovative biotech assets in an increasingly competitive therapeutic development landscape.